Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of ex vivo expanded autologous immune killer cells in stage IV non-small cell lung cancer who failed prior therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ex Vivo Expanded Autologous Immune Killer Cells (IKC)

Snippet

Sponsor: Ivy Life Sciences, Co., Ltd | Conditions: Non-small Cell Lung Cancer (NSCLC) Stage IV | Phase 2 | Status: COMPLETED